-
Mashup Score: 0Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML) - 10 month(s) ago
Leukemia – Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 13Are Hypomethylating Agents the Best First-Line Choice for Treating CMML? | ASH Clinical News | American Society of Hematology - 10 month(s) ago
Ioannis Kotsianidis, MD Mrinal M. Patnaik, MBBS The U.S. Food and Drug Administration has approved two hypomethylating agents (HMAs), azacitidine and decitabine, for the treatment of chronic myelomonocytic leukemia (CMML), a rare and aggressive myeloid malignancy with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).1,2 Despite being widely…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @MrinalPatnaik: Are Hypomethylating Agents the Best First-Line Choice for Treating CMML? https://t.co/qYm8gAjNY8 #CMML #DNMTi #TET2 @AS…
-
-
Mashup Score: 1July 2023 | ASH Clinical News | American Society of Hematology - 10 month(s) ago
July 2023 | ASH Clinical News | American Society of Hematology July 2023 Additional Fellowships: What’s the Value? For hematologists interested in specialized areas of practice, the decision to pursue additional training involves weighing financial considerations, research time, and career opportunities. Viewpoints Editor’s Corner Born to Lose From the Desk Of… Videos From…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
The July issue is out now! Follow the link below to access the latest in the #hematology literature, a feature on advanced, non-ACGME accredited #fellowships, a debate on #azacitidine for #CMML, and more: https://t.co/n273wBzs2D https://t.co/uuDNDa8ERF
-
-
Mashup Score: 2Are Hypomethylating Agents the Best First-Line Choice for Treating CMML? | ASH Clinical News | American Society of Hematology - 10 month(s) ago
Ioannis Kotsianidis, MD Mrinal M. Patnaik, MBBS The U.S. Food and Drug Administration has approved two hypomethylating agents (HMAs), azacitidine and decitabine, for the treatment of chronic myelomonocytic leukemia (CMML), a rare and aggressive myeloid malignancy with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).1,2 Despite being widely…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Are Hypomethylating Agents the Best First-Line Choice for Treating CMML? https://t.co/qYm8gAjNY8 #CMML #DNMTi #TET2 @ASH_hematology
-
-
Mashup Score: 0ASH Clinical News: July 2023 From the Desk Of... - 10 month(s) ago
Editor-in-Chief Aaron Gerds, MD, previews the forthcoming July 2023 issue of ASH Clinical News. Highlights include a feature article that discusses the consi…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
Click below to see what's to come in the July issue of ASH Clinical News! @AaronGerds discusses issue highlights, including a feature story on pursuing advanced, non-ACGME accredited #fellowships, a debate on the use of #azacitidine for #CMML, and more 🩸 https://t.co/gaOwbgUrjv
-
-
Mashup Score: 3Targeting BET proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML - PubMed - 12 month(s) ago
Inhibition of PIM kinases is a potential novel strategy for overcoming BETi persistence in myeloid neoplasms. Our data supports further clinical investigation of this combination.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Targeting BET proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML - PubMed Fantastic work by Chris Letson @md_padron @MoffittNews #CMML #BETi @MoritzBinderMD @MFZlab @MayoCancerCare https://t.co/1oiPZY5dMh
-
-
Mashup Score: 2Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis - PubMed - 12 month(s) ago
Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis. https://t.co/IyNh0O9IPy | TET2 and classical monocytosis- spectrum across #CCUS and #CMML @LashoTerra @MayoCancerCare
-
-
Mashup Score: 7
Leukemia – Activity of venetoclax-based therapy in chronic myelomonocytic leukemia
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @smbenlazar: Activity of venetoclax-based therapy in chronic myelomonocytic leukemia https://t.co/JNadpIsx17 #CMML https://t.co/NPqXIHZy…
-
-
Mashup Score: 0
Leukemia – Activity of venetoclax-based therapy in chronic myelomonocytic leukemia
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia https://t.co/JNadpIsx17 #CMML https://t.co/NPqXIHZyyL
-
-
Mashup Score: 0
Former prime minister, 86, is being treated for lung infection at Milan’s San Raffaele hospital
Source: the GuardianCategories: Hematologists1, Latest HeadlinesTweet-
Silvio Berlusconi living with leukaemia for some time, doctor confirms. It is #CMML, a form of #MDS https://t.co/rgxdTsJHaZ
-
#TP53 allelic status and CN-LOH in #CMML -Infrequent but relevant. Isochromosome 17q with monocytosis associated with poor outcomes @MarkGurneyOne @MayoCancerCare @md_padron @MoffittNews @LashoTerra https://t.co/BWoO94lIoh